Ítem
Acceso Abierto

Retail price regulation and innovation: Reference pricing in the pharmaceutical industry

Mostrar el registro sencillo de la publicación
dc.creatorBardey D.spa
dc.creatorBommier A.spa
dc.creatorJullien B.spa
dc.date.accessioned2020-05-25T23:56:12Z
dc.date.available2020-05-25T23:56:12Z
dc.date.created2010spa
dc.description.abstractOur paper is a first attempt to evaluate the long run impact of reference pricing on pharmaceutical innovation, health and expenditures. The model is based on a dynamic game involving three types of agents: pharmaceutical firms, consumers and a regulatory entity. Pharmaceutical firms choose the level of research investment and its innovative content, then negotiate introductory prices for new drugs with the regulator. Reference pricing affects negatively the intensity of research and it also modifies the types of innovations that are brought to the market, deterring small innovations. The model is calibrated with a small data on statins in France. Our results suggest that reference pricing typically generates a decline in health, whereas discounted expenditures may decrease or increase, depending on the degree of deterrence of cost reducing innovations. © 2009 Elsevier B.V.eng
dc.format.mimetypeapplication/pdf
dc.identifier.doihttps://doi.org/10.1016/j.jhealeco.2009.11.015
dc.identifier.issn1676296
dc.identifier.urihttps://repository.urosario.edu.co/handle/10336/22361
dc.language.isoengspa
dc.relation.citationEndPage316
dc.relation.citationIssueNo. 2
dc.relation.citationStartPage303
dc.relation.citationTitleJournal of Health Economics
dc.relation.citationVolumeVol. 29
dc.relation.ispartofJournal of Health Economics, ISSN:1676296, Vol.29, No.2 (2010); pp. 303-316spa
dc.relation.urihttps://www.scopus.com/inward/record.uri?eid=2-s2.0-77950627391&doi=10.1016%2fj.jhealeco.2009.11.015&partnerID=40&md5=a1e4077e5654051d5a67cf36da95bd07spa
dc.rights.accesRightsinfo:eu-repo/semantics/openAccess
dc.rights.accesoAbierto (Texto Completo)spa
dc.source.instnameinstname:Universidad del Rosariospa
dc.source.reponamereponame:Repositorio Institucional EdocURspa
dc.subject.keywordAtorvastatinspa
dc.subject.keywordFluindostatinspa
dc.subject.keywordHydroxymethylglutaryl coenzyme a reductase inhibitorspa
dc.subject.keywordPravastatinspa
dc.subject.keywordRosuvastatinspa
dc.subject.keywordSimvastatinspa
dc.subject.keywordDrugspa
dc.subject.keywordHealth expenditurespa
dc.subject.keywordIndustrial regulationspa
dc.subject.keywordInnovationspa
dc.subject.keywordModelingspa
dc.subject.keywordPharmaceutical industryspa
dc.subject.keywordPricing policyspa
dc.subject.keywordRetailingspa
dc.subject.keywordArticlespa
dc.subject.keywordDrug costspa
dc.subject.keywordDrug industryspa
dc.subject.keywordDynamicsspa
dc.subject.keywordHealth care costspa
dc.subject.keywordHumanspa
dc.subject.keywordMathematical analysisspa
dc.subject.keywordPharmaceutical carespa
dc.subject.keywordWelfarespa
dc.subject.keywordBiomedical researchspa
dc.subject.keywordDrug costsspa
dc.subject.keywordDrug industryspa
dc.subject.keywordDrugseng
dc.subject.keywordModelseng
dc.subject.keywordModelseng
dc.subject.keywordFrancespa
dc.subject.keywordInnovationspa
dc.subject.keywordMe-toospa
dc.subject.keywordPharmaceutical laboratoriesspa
dc.subject.keywordReference pricingspa
dc.titleRetail price regulation and innovation: Reference pricing in the pharmaceutical industryspa
dc.typearticleeng
dc.type.hasVersioninfo:eu-repo/semantics/publishedVersion
dc.type.spaArtículospa
Archivos
Bloque original
Mostrando1 - 1 de 1
Miniatura
Nombre:
1-s2-0-S016762960900143X-main.pdf
Tamaño:
651.81 KB
Formato:
Adobe Portable Document Format
Descripción:
Descargar
Colecciones
Artículos